Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-04T21:00:54.971Z Has data issue: false hasContentIssue false

27 - The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath

Published online by Cambridge University Press:  19 January 2024

Daniel Gibbs
Affiliation:
Emeritus of Oregon Health and Science University
Get access

Summary

The amyloid hypothesis has been the dominant theory for the cause of Alzheimer’s disease for over 20 years. In brief, the theory holds that Alzheimer’s disease is caused by the accumulation of beta-amyloid that damages nerve cells in the brain. Beta-amyloid is cleaved from the large amyloid precursor protein (APP) into two main peptides that are released outside the cell, beta-amyloid 40 and beta-amyloid 42, containing respectively 40 and 42 amino acids. According to the amyloid hypothesis, in normal people, these peptides are rapidly removed, but in people with Alzheimer’s disease the metabolic ability to degrade them is decreased, the peptides accumulate, form fibrils, and ultimately solid amyloid plaques that in turn damage neurons and trigger the formation of abnormal tau pathology causing neuronal death.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kametani, F, Hasegawa, M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci 2018; 12: 25. https://doi.org/10.3389/fnins.2018.00025. PMID: 29440986; PMCID: PMC5797629 (open access).CrossRefGoogle ScholarPubMed
Cummings, JL, Goldman, DP, Simmons-Stern, NR, Ponton, E. The costs of developing treatments for Alzheimer’s disease: A retrospective exploration. Alzheimers Dement 2021; 18: 469477. https://doi.org/10.1002/alz.12450 (open access).CrossRefGoogle ScholarPubMed
Van Dyck, CH, Swanson, CJ, Aisen, P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388: 921. https://doi.org/10.1056/NEJMoa2212948CrossRefGoogle ScholarPubMed
Knopman, DS, Jones, DT, Greicius, MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 2021; 17: 696701. https://doi.org/10.1002/alz.12213 (open access).CrossRefGoogle ScholarPubMed
Rogers, MB. API Colombian trial of crenezumab missed primary endpoints. Alzforum. June 18, 2022. www.alzforum.org/news/research-news/api-colombian-trial-crenezumab-missed-primary-endpoints (open access)Google Scholar
Eli Lilly and Company Press Release. Update on A4 study of solanezumab for preclinical Alzheimer’s disease. March 8, 2023. https://a4study.org/study-results/ (open access).Google Scholar
Lesné, S, Koh, M, Kotilinek, Let alA specific amyloid-β protein assembly in the brain impairs memory. Nature 2006; 440: 352357. https://doi.org/10.1038/nature04533.CrossRefGoogle ScholarPubMed
Espay, AJ, Sturchio, A, Schneider, LS, Ezzat, K. Soluble amyloid-β consumption in Alzheimer’s disease. J Alzheimers Dis 2021; 82(4): 14031415. https://doi.org/10.3233/JAD-210415; PMID: 34151810.CrossRefGoogle ScholarPubMed
Rogers, MB. Sylvain Lesné, who found Aβ*56, accused of image manipulation. Alzforum. July 22, 2022; see comment by Dr. Grace Stutzmann. www.alzforum.org/news/community-news/sylvain-lesne-who-found-av56-accused-image-manipulation (open access).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×